The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?

International Journal of Drug Policy

Volumn 26, Issue 10, 2015, Pages 963-969

  Harris, Magdalena ^a   Albers, Eliot ^b   Swan, Tracy ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b International Network of People Who Use Drugs   (United Kingdom)

^c Treatment Action Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT;

AGE; BASIC NEEDS; CLINICAL EFFECTIVENESS; CONTROL STRATEGY; CRIME; DETENTION; HARM REDUCTION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; NAMED GROUPS OF PERSONS; NEEDLE AND SYRINGE PROGRAM; NOTE; OPIATE SUBSTITUTION TREATMENT; PEOPLE WHO INJECT DRUGS; PRIORITY JOURNAL; SOCIAL DISCRIMINATION; STIGMA; TREATMENT AS PREVENTION STRATEGY; TREATMENT REFUSAL; VIRUS TRANSMISSION; COMPLICATION; HEALTH CARE DELIVERY; HIV INFECTIONS; NEEDS ASSESSMENT; SUBSTANCE ABUSE; TRANSMISSION;

ANTIVIRAL AGENTS; HARM REDUCTION; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HIV INFECTIONS; HUMANS; NEEDS ASSESSMENT; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84941805668     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.05.005     Document Type: Note

References (68)

1. Adam B. Epistemic fault lines in biomedical and social approaches to HIV prevention. Journal of the International AIDS Society 2011, 14(Suppl. 2):S3.
2. Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine 2014, 15(20):370.
3. Alavi M., Grebely J., Micallef M., Dunlop A.J., Balcomb A.C., Day C.A., et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS Study. Clinical Infectious Diseases 2013, 57(Suppl. 2):S62-S69.
4. Aspinall E.J., Corson S., Doyle J.S., Grebely J., Hutchinson S.J., Dore G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases 2013, 57(Suppl. 2):S80-S89.
5. Barr D., Amon J.J., Clayton M. Articulating a rights-based approach to HIV treatment and prevention interventions. Current HIV Research 2011, 9(6):396-404.
6. Bobrova N., Sarang A., Stuikyte R., Lezhentsev K. Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: A regional overview. International Journal of Drug Policy 2007, 18:313-318.
7. Bourgois P., Prince B., Moss A. The everyday violence of hepatitis C among young women who inject drugs in San Francisco. Human Organization 2004, 63(3):253.
8. Bruggmann P., Litwin A.H. Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all. Clinical Infectious Diseases 2013, 57(Suppl. 2):S56-S61.
9. Canfield K., Smyth E., Batki S. Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Substance Use and Misuse 2010, 45(4):496-514.
10. Centers for Disease Control and Prevention Estimated HIV incidence in the United States, 2007-2010. HIV Surveillance Supplemental Report 2012, 17(No. 4).
11. Centers for Disease Control and Prevention CDC's new high-impact approach to HIV prevention funding for health departments 2014, http://www.cdc.gov/hiv/policies/funding/announcements/PS12-1201/factsheet.html Accessed 2.09.14.
12. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine 2011, 365(6):493-505.
13. Cook C., Bridge J., McLean S., Phelan M., Barrett D. The funding crisis for harm reduction 2014, Harm Reduction International, London, ISBN 978-0-9927609-1-5.
14. Crawford S., Bath N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clinical Infectious Diseases 2013, 57(Suppl. 2):S75-S79.
15. Doab A., Treloar C., Dore G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases 2005, 40(S5):S313-S320.
16. Duff C., Moore D. Counterpublic health and the design of drug services for methamphetamine consumers in Melbourne. Health 2015, 19(1):51-66.
17. Durier N., Nguyen C., White L.J. Treatment of hepatitis C as prevention: A modeling case study in Vietnam. PLoS ONE 2012, 7(4):e34548.
18. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C 2014 2014, European Association for the Study of the Liver, Geneva.
19. Fraser S., Moore D. Harm reduction and hepatitis C: On the ethics and politics of prevention and treatment. Addiction Research & Theory 2011, 19(4):375-379.
20. Friedman S., Downing M., Smyrnov P., Nikolopoulos G., Schneider J., Livak B., et al. Socially-integrated transdisciplinary HIV prevention. AIDS and Behavior 2014, 18(10):1821-1834.
21. Grebely J., Dore G. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research 2014, 104:62-72.
22. Hagan L.M., Wolpe P.R., Schinazi R.F. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends in Microbiology 2013, 21(12):625-633.
23. Harris M., Martin A., Rhodes T. Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. Social Science & Medicine 2013, 83:19-26.
24. Harris M., Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduction Journal 2013, 10(7).
25. Harris M., Rhodes T. Injecting practices in sexual partnerships: Hepatitis C transmission potentials in a 'risk equivalence' framework. Drug and Alcohol Dependence 2013, 132(3):617-623.
26. Harris M., Rhodes T. The future of hepatitis C care: Taking PWID needs and perspectives into account. EMCDDA insights: Hepatitis C virus infection treatment among people who inject drugs 2015, EMCDDA, Lisbon. N. Martin, M. Hickman (Eds.).
27. Hellard M., Doyle D., Sacks-Davis R., Thompson A., McBryde E. Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology 2014, 59(2):366-369.
28. Henderson K., Worth H., Aggleton P., Kippax S. Enhancing HIV prevention requires addressing the complex relationship between prevention and treatment. Global Public Health 2009, 4(2):117-130.
29. Innes H., Goldberg D., Dillon J., Hutchinson S.J. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: What public health outcomes do we value most?. Gut 2014, 10.1136/gutjnl-2014-308166.
30. Innes H., Goldberg D., Dusheiko G., Hayes P., Mills P.R., Dillon J.F., et al. Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. Journal of Hepatology 2014, 60(6):1118-1126.
31. Jacobsen H. Greece reintroduces forced HIV testing 2013, http://www.euractiv.com/health/greece-reintroduces-forced-hiv-t-news-529255 Retrieved 13.10.14.
32. Johnson J. Forgotten negatives: The limits of treatment as prevention. Treatment Action Group 2014, Available at: http://www.treatmentactiongroup.org/tagline/2014/spring/forgotten-negatives-limits-treatment-prevention.
33. Jürgens R., Csete J., Amon J.J., Baral S., Beyrer C. People who use drugs, HIV, and human rights. The Lancet 2010, 376(9739):475-485.
34. Kippax S. Reasserting the social in a biomedical epidemic: The case of HIV prevention 2010, Paper presented at Reframing the social dimensions of HIV in a biomedicalised epidemic: The case of treatment as prevention, London, UK.
35. Kippax S. Effective HIV prevention: The indispensable role of social science. Journal of the International AIDS Society 2012, 15(17357):1-8.
36. Krusi A., Wood E., Montaner J., Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. International Journal of Drug Policy 2010, 21:4-9.
37. Kwon J.A., Iversen J., Maher L., Law M.G., Wilson D.P. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: A model-based analysis. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2009, 51(4):462-469.
38. Larney S., Beckwith C., Zaller N., Montague B., Rich J. Seek, test, treat and retain for hepatitis C in the United States criminal justice system. International Journal of Prisoner Health 2014, 10(3):164-171. 10.1108/IJPH-11-2013-0051.
39. Lazarus J., Lundgren J., Casabona J., Wiessing L., Mathei C., Vickerman P., et al. Roundtable discussion: How lessons learned from HIV can inform the global response to viral hepatitis. BMC Infectious Diseases 2014, 14(Suppl. 6):S18.
40. Levy M.H., Larney S. The ethics of hepatitis C treatment as prevention among prisoners. Hepatology 2014, 61(1):402. 10.1002/hep.27195.
41. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R.P., et al. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. The Lancet 2010, 375(9719):1014-1028.
42. Martin N.K., Hickman M., Hutchinson S.J., Goldberg D.J., Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases 2013, 57(Suppl. 2):S39-S45.
43. Martin N.K., Vickerman P., Grebely J., Hellard M., Hutchinson S.J., Lima V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013, 58(5):1598-1609.
44. Médecins du Monde and International Network of People who use Drugs Nobody left behind: The importance of integrating people who inject drugs into HCV treatment programs. Arguments from a public health and human rights perspective 2014, Available from: http://www.inpud.net/201406-MDM-policy-VHC-en-NobodyLeftBehind.pdf.
45. Medecins Sans Frontieres Barriers to access and scale up of Hepatitis C (HCV) treatment - Gilead's anti-diversion program 2014, Medecins Sans Frontieres, Geneva.
46. Milloy M.J., Montaner J., Wood E. Barriers to HIV treatment among people who use injection drugs: Implications for 'treatment as prevention'. Current Opinion in HIV & AIDS 2012, 7(4):332-338.
47. Nguyen V.-K., Bajos N., Dubois-Arber F., O'Malley J., Pirkle C.M. Remedicalizing an epidemic: From HIV treatment as prevention to HIV treatment is prevention. AIDS 2011, 25(3):291-293.
48. Norman J., Walsh N., Mugavin J., Stoove M., Kelsall J., Austin K., et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduction Journal 2008, 5(8).
49. Page K., Morris M.D., Hahn J.A., Maher L., Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: Using evidence to inform comprehensive prevention. Clinical Infectious Diseases 2013, 57(Suppl. 2):S32-S38.
50. Public Health England HIV and STIs in men who have sex with men in London 2014, Public Health England, London.
51. Rhodes T., Harris M., Martin A. Negotiating access to medical treatment and the making of patient citizenship: The case of hepatitis C treatment. Sociology of Health & Illness 2013, 35(7):1023-1044.
52. Rodger A., Bruun T., Cambiano V., Vernazza P., Estrada V., Van Lunzen J., et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER Study. Abstract 153LB 2014, Paper presented at the CROI 2014, Boston, MA.
53. Rolls D.A., Sacks-Davis R., Jenkinson R., McBryde E., Pattison P., Robins G.L., et al. Hepatitis C transmission and treatment in contact networks of people who inject drugs. PLOS ONE 2013, 8(11):1-15.
54. Ryder S., Dillon J. Eradicating hepatitis C is a realistic aim. Health Service Journal 2014.
55. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 2014, 370(3):211-221.
56. Sussman N.L., Remien C.H., Kanwal F. The end of hepatitis C. Clinical Gastroenterology and Hepatology 2014, 12(4):533-536.
57. Swan T. Bonanza! The gold rush is underway. HIV i-base/treatment action group pipeline report 2014, Available at: http://www.pipelinereport.org/2014/hcv-pipeline.
58. Swan D., Long J., Carr O., Flanagan J., Irish H., Keating S., et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care & STDs 2010, 24(12):753-762.
59. Treloar C., Rance J. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting. International Journal of Drug Policy 2014, 25(5):865-870.
60. Treloar C., Hull P., BSamt J., Hopwood M., Grebely J., Lavis Y. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. Drug and Alcohol Dependence 2011, 116(1-3):52-56.
61. Treloar C., Rance J., Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clinical Infectious Diseases 2013, 57(Suppl. 2):S51-S55.
62. Warner M. Publics and counterpublics. Public Culture 2002, 14:49-90.
63. Wood E., Kerr T., Marshall B.D., Li K., Zhang R., Hogg R.S., et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: Prospective cohort study. British Medical Journal 2009, 338:b1649.
64. World Health Organisation WHO, UNODC UNAIDS technical guide 2009, World Health Organisation, Geneva.
65. World Health Organisation Consolidated ARV guidelines 2013, Available at: http://www.who.int/hiv/pub/guidelines/arv2013/intro/rag/en/index2.html.
66. World Health Organisation Guidelines for the screening, care and treatment of persons with hepatitis C infection 2014, World Health Organisation, Geneva.
67. World Health Organisation Regional Office for Europe Barriers and facilitators to hepatitis C treatment for people who inject drugs: A qualitative study 2012, WHO Regional Office for Europe, Copenhagen.
68. World Trade Organisation TRIPS and pharmaceutical patents. Factsheet 2006, https://www.wto.org/ENGLISH/tratop_e/trips_e/factsheet_pharm00_e.htm Accessed 2.09.14.